Cargando…

Clinical Characteristics and Prognosis of HER2 Gene Phenotype in Patients with Non-Small Cell Lung Cancer

INTRODUCTION: We aim to investigate the relationship between HER2 gene phenotype and clinical characteristics, distribution and prognosis of non-small cell lung cancer (NSCLC) patients. METHODS: A total of 249 NSCLC patients admitted to the oncology department of our hospital from January 2015 to Ja...

Descripción completa

Detalles Bibliográficos
Autores principales:	Diao, Wei-Ying, Ding, Cheng-Long, Yuan, Bo-Yang, Li, Zan, Sun, Na, Huang, Jia-Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646112/ https://www.ncbi.nlm.nih.gov/pubmed/34880654 http://dx.doi.org/10.2147/IJGM.S328908

Ejemplares similares

Expression and Clinical Significance of HER2 Gene and DNMT1 in Non-Small-Cell Lung Cancer
por: Diao, Weiying, et al.
Publicado: (2022)

Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer
por: Jacot, W, et al.
Publicado: (2004)

Analysis of the characteristics and prognosis of advanced non-small-cell lung cancer in older patients
por: Gao, Ying, et al.
Publicado: (2015)

Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea
por: Lee, Kangkook, et al.
Publicado: (2020)

Consensus for HER2 alterations testing in non-small-cell lung cancer
por: Ren, S., et al.
Publicado: (2022)

Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2
por: Takeda, Masayuki, et al.
Publicado: (2018)

Genomic and immune characteristics of HER2‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy
por: Tu, Hai‐Yan, et al.
Publicado: (2023)

HER3 expression and MEK activation in non-small-cell lung carcinoma
por: Manickavasagar, Thubeena, et al.
Publicado: (2021)

Genomic landscape and efficacy of HER2-targeted therapy in patients with HER2-mutant non-small cell lung cancer
por: Han, Yanjie, et al.
Publicado: (2023)

Newly diagnosed non‐small cell lung cancer with interstitial lung abnormality: Prevalence, characteristics, and prognosis
por: Zhu, Min, et al.
Publicado: (2023)

Treatment outcome and clinical characteristics of HER2 mutated advanced non‐small cell lung cancer patients in China
por: Xu, Fei, et al.
Publicado: (2020)

Molecular Characteristics and the Effect of KRAS Mutation on the Prognosis of Immunotherapy in Non-Small Cell Lung Cancer in Xinjiang, China
por: Gu, Guomin, et al.
Publicado: (2022)

Platelet distribution width correlates with prognosis of non-small cell lung cancer
por: Cui, Ming-ming, et al.
Publicado: (2017)

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
por: Agostinetto, Elisa, et al.
Publicado: (2021)

HER2 mutations in Chinese patients with non-small cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2016)

Genomic characteristics in Chinese non-small cell lung cancer patients and its value in prediction of postoperative prognosis
por: Zhang, Bin, et al.
Publicado: (2020)

Clinical characteristics and prognosis of non-small cell lung cancer patients with liver metastasis: A population-based study
por: Wang, Jun-Feng, et al.
Publicado: (2022)

Ring finger protein 38 promote non-small cell lung cancer progression by endowing cell EMT phenotype
por: Xiong, Dian, et al.
Publicado: (2018)

Distribution and prognosis of uncommon metastases from non-small cell lung cancer
por: Niu, Fei-Yu, et al.
Publicado: (2016)

Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis
por: Yuan, Xun, et al.
Publicado: (2015)

SMOX expression predicts the prognosis of non-small cell lung cancer
por: Huang, Zhanghao, et al.
Publicado: (2021)

Former smokers with non‐small‐cell lung cancers: a comprehensive investigation of clinicopathologic characteristics, oncogenic drivers, and prognosis
por: Zheng, Shanbo, et al.
Publicado: (2016)

Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma
por: Shan, Ling, et al.
Publicado: (2015)

Clinicopathological Characteristics and Prognosis of Non-Small Cell Lung Cancer Patients Associated with a Family History of Lung Cancer
por: Haraguchi, Shuji, et al.
Publicado: (2011)

Non-small cell lung cancer: quantitative phenotypic analysis of CT images as a potential marker of prognosis
por: Song, Jiangdian, et al.
Publicado: (2016)

Construction of a Nomogram Based on lncRNA and Patient’s Clinical Characteristics to Improve the Prognosis of Non-Small Cell Lung Cancer
por: Wang, Helin, et al.
Publicado: (2022)

Cav3.1 overexpression is associated with negative characteristics and prognosis in non-small cell lung cancer
por: Suo, Aleksi, et al.
Publicado: (2018)

Correlation Analysis of the TP53 Mutation With Clinical Characteristics in the Prognosis of Non–Small Cell Lung Cancer
por: Zhu, Lihuan, et al.
Publicado: (2023)

Serum cholinesterase may independently predict prognosis in non-small-cell lung cancer
por: Ran, Hailiang, et al.
Publicado: (2022)

Progress in Treatment of Non-Small Cell Lung Cancer Harboring HER2 Aberrations
por: Ni, Jun, et al.
Publicado: (2021)

HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies
por: Uy, Natalie F., et al.
Publicado: (2022)

Chinese expert consensus on the diagnosis and treatment of HER2‐altered non–small cell lung cancer
por: Zhang, Shirong, et al.
Publicado: (2022)

Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02–14
por: Auliac, Jean-Bernard, et al.
Publicado: (2019)

GNPNAT1 Predicts Poor Prognosis and Cancer Development in Non-Small Cell Lung Cancer
por: Feng, Yong, et al.
Publicado: (2022)

Poziotinib in non-small-cell lung cancer patients with HER2 exon 20 mutations: A pooled analysis of randomized clinical trials
por: Wang, Bi-Cheng, et al.
Publicado: (2022)

Radiotherapy Dose and Induction Chemotherapy Cycles Are Associated With Prognosis and Toxicity Risk: A Retrospective Study of 227 Patients With Unresectable Stage III Non-Small-Cell Lung Cancer
por: Chen, Liyao, et al.
Publicado: (2020)

Real World Characteristics and Clinical Outcomes of HER2-Mutant Non–Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing
por: Ahn, Beung-Chul, et al.
Publicado: (2023)

Molecular gene signature and prognosis of non-small cell lung cancer
por: Huang, Poyin, et al.
Publicado: (2016)

Clinicopathologic characteristics and outcomes of Chinese patients with non‐small‐cell lung cancer and BRAF mutation
por: Ding, Xi, et al.
Publicado: (2017)

Comprehensive Analysis of the Molecular Characteristics and Prognosis value of AT II-associated Genes in Non-small Cell Lung Cancer
por: Ren, Liping, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_698ovlnat10es68pb9kmo2hmqr